United Cannabis: Bridging the Gap in MMJ Patient Care (Plus Exclusive CEO Interview)
May 11th, 2017
News, Top News
The legalization of cannabis across North America has created a multi-billion dollar industry in short order, but there is still a lot of uncertainty surrounding the medical use of cannabis. Many physicians are still unwilling to prescribe the drug, which has left patients in limbo when determining the right strains to treat their medical needs. The good news is that some companies are working on bridging this gap.
In this article, we will take a look at United Cannabis Inc.’s (OTCQB: CNAB) naturopathic approach to the cannabis industry and its plans to build shareholder value. See an exclusive interview with CEO Earnie Blackmon here:
Bridging the Gap with Patients
United Cannabis has developed a complete line-up of cannabinoids that are licensed to regulated dispensaries. In addition, the company’s A.C.T. Now program helps patients mix and match cannabinoids for therapeutic purposes. These products and services are designed to help bridge the gap between providing legal access to cannabis and helping patients effectively treat serious medical conditions at a time when many physicians remain skeptical.
The company’s Prana Bio Medicinal cannabinoid products use a patent-pending infusion process utilizing select fatty acids, lipids, and specific combinations of cannabis-derived terpenes to increase bioavailability. The capsules are packaged in airtight blister packs for 10-30-60 day regimen and are formulated with full-spectrum (e.g. whole plant) cannabis derived terpenes with various percentages of CBD and THC.
When a patient signs up for the complementary A.C.T. Now service, which comes free with Prana Bio Medicinal purchases, they are assigned to a nurse that will assess his or her current medications and create a personalized program for them. The patients then rely on a robust HIPPA-compliant cloud-based software to record their health conditions, schedule follow-ups, and continue to fine-tune their programs with their assigned health professional.
United Cannabis’ Chief Executive Officer, Earnest Blackmon, and Chief Technical Officer, Tony Verzura, have been involved with medical cannabis since it was permissible in California in 1999. In 2009, they turned their focus to Colorado when medical cannabis was legalized. The team has more than 30 years of combined experience in the industry, including engineered facilities, security, regulatory compliance, genetics, cultivation, manufacturing, extraction, branding, and retail operations.
Since 2009, the company has accumulated observational data from more than 15,000 medical marijuana patients that have successfully used its Prana Bio and A.C.T. Now programs. These efforts caught the attention of prominent members of the medical community, including Brent Reynolds, Ph.D. and Dr. Barry Bialek, who went on to join the company’s Medical Advisory Board to help further develop its programs.
This highly-qualified team is committed to advancing the use of cannabinoid-based medicine with a focus on the refinement of genetics for medical-grade strains of CBD-rich cannabis plants. The company is also dedicated to bringing best practices across all areas of the industry, including operation, planning, products, governance, and patient care.
Rapidly Growing Market
The North American cannabis industry has experienced rapid growth following the liberalization of marijuana laws in the United States and Canada.
The U.S. cannabis industry could reach $50 billion in size by 2026, according to Cowen & Co., driven by the recreational legalization of marijuana in California and other states. While the tobacco industry could account for a fifth of the industry by 2016, the companies that have established themselves early on could be best positioned to profit over the long-term given medical marijuana patient trust and established branding.
In Canada, Deloitte estimates that the cannabis industry could reach $22.6 billion in size over the coming years as recreational legalization goes into effect nationwide. The retail market for the drug could be worth upwards of $8.7 billion per year, while marijuana-related products and services – such as growing, testing, and lighting – could increase that figure to between $12.7 billion and $22.6 billion – a significant market by any measure.
United Cannabis Inc. (OTCQB: CNAB) plans to capitalize on the rapidly growing North American cannabis industry. In the U.S., the company’s Prana Bio Medicinal brand provides patients with a comprehensive service designed to help them select the right medicine to treat chronic pain and manage their care over time. The company is also actively pursuing clinical trials to validate the effectiveness of its products in treating serious medical conditions.
In January, the company signed an agreement with the Caribbean Institute of Medical Research to collaborate on advancing clinical trials on medical cannabis. Under the letter of intent, studies will be conducted under the supervision of the CARIMER team who will be responsible for initiating the research and clinical trials fro Prama P1-P5 products. Pre-clinical studies will focus on areas like acute and chronic toxicology, as well as dosing escalation and safety studies.
Investors may want to keep an eye on the company as it continues to execute on its vision to become a leader in medical cannabis products and services.
For more information, visit the company’s website at www.unitedcannabis.us.
Follow Us on Social Media
About CFN Media
CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.
CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.
Disclaimer: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.